News

Aprea Therapeutics AB president and CEO Christian Schade said: "The initiation of the Phase II clinical study marks an important milestone for Aprea. "We are committed to developing and

SCIB2 will be studied in combination with a checkpoint inhibitor and follow the publication of data in journal OncoImmunology, which showed the drug demonstrated potent anti-tumour immunity. Data

The sBLA was submitted by Genmab's licensing partner, Janssen Biotech, Inc. in August 2016. Priority Review is an FDA designation for drugs that treat a serious condition and

The findings will be presented during a poster discussion session (Abstract #774PD) on October 9 at the European Society for Medical Oncology (ESMO) 2016 Congress, which is being

The injection has been approved as a short-term replacement therapy for oral carbamazepine formulations in adults with certain seizure types when oral administration is temporarily not possible. It

The agreement was reached through the Special Protocol Assessment (SPA) process. A SPA is an acknowledgement by FDA that the design and planned analysis of the Company's pivotal

Kymo Therapeutics’s ambition is to move forward Metabrain Research’s proprietary program on kynurenine metabolism (KMO) inhibitors towards clinical proof of concept, before seeking partners to complete development and

The trial is designed to evaluate the safety and efficacy of the combination in patients with refractory diffuse large B-cell lymphoma (DLBCL). PD-L1 expression in DLBCL is associated

The drug, called Zubsolv, is a formulation of buprenorphine, a semisynthetic opioid derivative of thebaine, and naloxone, an opioid overdose antidote. The new low dose, 0.7mg/0.18 mg, Zubsolv